外部三叉神经刺激在神经与精神障碍中的临床与认知效应:系统综述与荟萃分析
结果显示,eTNS联合抗偏头痛药物可显著改善偏头痛疼痛强度(SMD=1.03,95%CI[0.84-1.23])和生活质量(SMD=1.88,95%CI[1.22-2.53]),抑郁维度测量在3种障碍中改善(SMD=0.45,95%CI[0.01-0.88]),且耐受性良好。
要点
- eTNS联合抗偏头痛药物可显著改善偏头痛疼痛强度和生活质量。
- eTNS对3种障碍的抑郁维度测量有改善,SMD=0.45(95%CI[0.01-0.88])。
- eTNS耐受性良好,不良事件特征良好;但需充分盲法、足够把握度的随机对照试验验证。
核心结论
- eTNS在偏头痛和抑郁维度测量中显示出潜在临床相关性,耐受性良好,但需更高质量随机对照试验重复验证并支持最佳剂量指导。
研究设计与样本
- 预注册系统综述与荟萃分析(CRD42022322038),检索PubMed、OVID、Web of Science、CNKI、万方和维普数据库至2022年3月16日。
- 荟萃分析人群年龄范围10-49岁,约3%注意缺陷多动障碍(ADHD)、约3%癫痫、约94%偏头痛。
- 使用Cochrane Risk of Bias 2.0工具评估随机对照试验,使用ROBINS-I评估单臂试验。
主要发现
- 偏头痛疼痛强度在eTNS联合抗偏头痛药物下显著改善(K=4,N=485;SMD=1.03,95%CI[0.84-1.23])。
- 偏头痛生活质量在eTNS联合抗偏头痛药物下显著改善(K=2,N=304;SMD=1.88,95%CI[1.22-2.53])。
- 抑郁维度测量在3种不同障碍中随eTNS改善(K=3,N=111;SMD=0.45,95%CI[0.01-0.88])。
- eTNS在各障碍中耐受性良好,不良事件特征良好。
临床怎么用
- eTNS可作为偏头痛联合抗偏头痛药物治疗的辅助手段,可能改善疼痛强度和生活质量。
- eTNS可能对合并抑郁维度的多种障碍有潜在益处,但需进一步验证。
- 临床使用eTNS时需注意其耐受性良好,但最佳剂量尚需充分把握度的随机对照试验确定。
局限性
- 荟萃分析纳入的12项试验中约94%为偏头痛,其他障碍证据有限。
- 需要充分盲法、足够把握度的随机对照试验重复验证 findings 并支持最佳剂量指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This pre-registered (CRD42022322038) systematic review and meta-analysis investigated clinical and cognitive outcomes of external trigeminal nerve stimulation (eTNS) in neurological and psychiatric disorders. PubMed, OVID, Web of Science, Chinese National Knowledge Infrastructure, Wanfang, and VIP database for Chinese technical periodicals were searched (until 16/03/2022) to identify trials investigating cognitive and clinical outcomes of eTNS in neurological or psychiatric disorders. The Cochrane Risk of Bias 2.0 tool assessed randomized controlled trials (RCTs), while the Risk of Bias of Non-Randomized Studies (ROBINS-I) assessed single-arm trials. Fifty-five peer-reviewed articles based on 48 (27 RCTs; 21 single-arm) trials were included, of which 12 trials were meta-analyzed (N participants = 1048; of which ~3% ADHD, ~3% Epilepsy, ~94% Migraine; age range: 10-49 years). The meta-analyses showed that migraine pain intensity (K trials = 4, N = 485; SMD = 1.03, 95% CI[0.84-1.23]) and quality of life (K = 2, N = 304; SMD = 1.88, 95% CI[1.22-2.53]) significantly improved with eTNS combined with anti-migraine medication. Dimensional measures of depression improved with eTNS across 3 different disorders (K = 3, N = 111; SMD = 0.45, 95% CI[0.01-0.88]). eTNS was well-tolerated, with a good adverse event profile across disorders. eTNS is potentially clinically relevant in other disorders, but well-blinded, adequately powered RCTs must replicate findings and support optimal dosage guidance.
引用
- Westwood SJ, Conti AA, Tang W, et al. Clinical and cognitive effects of external trigeminal nerve stimulation (eTNS) in neurological and psychiatric disorders: a systematic review and meta-analysis. Mol Psychiatry. 2023. PMID: 37674019. doi:10.1038/s41380-023-02227-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。